Valneva and LimmaTech Biologics have entered into a strategic partnership and exclusive licensing agreement aimed at accelerating the development of a Shigella vaccine candidate. There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally. The new agreement gives Valneva an exclusive global licence for LimmaTech’s Shigella4V, a tetravalent bioconjugate vaccine that has already shown promise in a phase 1/2 trial. Source PM Live 9/8/2024